SNORD35B: SNORD35B is a small nucleolar RNA (snoRNA) that has been implicated in various diseases, including head and neck squamous cell carcinoma (HNSCC) and leukemia. In HNSCC, high expression levels of SNORD35B have been associated with a lower survival rate among patients [PMC5867855]. Additionally, SNORD35B has been identified as a prognostic factor for HNSCC, independently of established clinical risk parameters [PMC4436665]. In pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), elevated expression levels of SNORD35B have been linked to disease relapse [PMC8677010]. Similarly, in chronic B-cell lymphocytic leukemia (CLL), dysregulation of SNORD35B has been observed in response to proliferation and has potential as a biomarker for distinguishing between normal B-cells and CLL cases [PMC10050728]. Furthermore, SNORD35B has been found to be upregulated in relapsed BCP-ALL patients compared to those without relapse [PMC9413531]. In terms of its function, SNORD35B is involved in the methylation of 28S ribosomal RNA at residue C4506 [PMC4436665][PMC6466398]. Overall, the dysregulation and prognostic significance of SNORD35B make it an important target for further research in various diseases.